Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

The transforming growth factor β (TGF-β) pathway, which is well studied for its ability to
inhibit cell proliferation in early stages of tumorigenesis while promoting epithelial …

Various macro/microscopic biomaterials have been developed for controlled drug delivery in
the combination therapy of malignancies. However, uncertain loading ratio, release …

Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many
targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the …

Abtract Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the
normal development of several endoderm-derived organs, including the prostate gland …

HOXB13, a homeodomain transcription factor, critically regulates androgen receptor (AR)
activities and androgen-dependent prostate cancer (PCa) growth. However, its functions in …

Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American
men. While androgen deprivation has remained as the cornerstone of prostate cancer …

Epithelial–mesenchymal transition (EMT) is a program wherein epithelial cells lose their
junctions and polarity while acquiring mesenchymal properties and invasive ability …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or
acquired resistance to second-generation androgen-targeting therapies and minimal …